Shares in Intersect ENT (NSDQ:XENT) fell slightly today even though the drug-device company met expectations on Wall Street with its 4th quarter results.
The Menlo Park, Calif.-based company pared losses to -$4.8 million, or -17¢ per share, on sales of $24.2 million for the 3 months ended Dec. 31, for bottom-line growth of 15.8% on sales growth of 28.7% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were -17¢, ahead of consensus on The Street, where analysts were looking for sales of $23.1 million.
Get the full story at our sister site, Drug Delivery Business News.